RCVR (Residual CardioVascular Risk) Prospective Study

Residual CardioVascular Risk (RCVR) After Percutaneous Coronary Intervention: A Prospective Study

The goal of this observational study is to evaluate whether residual cardiovascular risk assessed at 1 month after percutaneous coronary intervention (PCI) is associated with long-term clinical outcomes in adult patients with coronary artery disease who are free from major adverse clinical events at 1 month after PCI. The main questions it aims to answer are:

• Does residual cardiovascular risk at 1 month after PCI predict long-term net adverse clinical events?
• Which components of residual cardiovascular risk are associated with subsequent adverse clinical outcomes?

Participants will:

• Undergo comprehensive laboratory testing at 1 month after PCI and annually thereafter.
• Undergo artificial intelligence-based quantitative coronary angiographic analysis using DICOM datasets after PCI.
• Be followed annually for up to 3 years after the 1-month assessment to evaluate clinical outcomes.

Inclusion Criteria:

• Patients who have undergone percutaneous coronary intervention.
• Patients who are free from death, myocardial infarction, stroke, unplanned revascularization, or major bleeding within 1 month after the index PCI.
• Patients who are able to undergo artificial intelligence-based quantitative coronary angiography using DICOM datasets.
• Patients who have provided written informed consent at the 1-month post-PCI visit.

Exclusion Criteria:

• Under 19 years of age.
• Pregnant, breastfeeding, or women of childbearing age.
• Currently has a malignancy or has a history of malignancy within the past 5 years.
• Life expectancy of less than 5 years.
• Occurrence of death, myocardial infarction, stroke, unplanned revascularization, or major bleeding within 1 month after the index PCI.
• Inability or unwillingness to comply with scheduled follow-up assessments.